As several third-generation CDK9 inhibitors such as AZD-4573, BAY1251152 and JSH-150 are currently undergoing clinical trials, our findings emphasize CDK9 as a promising molecular target for treating cervical cancer patients, especially those with low caspase-8 expression [21]. This evidence concerns the gene CASP8 and cervical cancer.